Australian pharmaceutical firm Hatchtech has appointment Timothy Waugh as chief executive.
Waugh has worked in the pharmaceutical industry for 27 years and has spent the last 10 years with Roche in the US as a divisional vice president.
Paul Kelly, Hatchtech’s chairman, said: ‘Tim’s skill set and extensive experience will be a strong addition and complement those existing in the company. The Board is confident this management team will serve us well as we take the company into the next stage of developing and commercialising DeOvo for the global marketplace.’
DeOvo is a topical formulation of a known metalloprotease inhibitor and offer the potential for a head lice control treatment that requires only one application.
Waugh said he looks forward to working with Hatchtech’s Board and management team as it review the results of the Phase IIb study and plan for the next stages of its clinical development.
Waugh will join the Board of Hatchtech and will be based in New Jersey, US.
Hatchtech appoints Tim Waugh as ceo
Formerly with Roche in the US as a divisional vice president
You may also like
Manufacturing
Lonza appoints Hans Trees as Global Head of Communications
Hans Trees will join Lonza as Global Head of Communications, Senior Vice President and Member of the Extended Executive Committee, effective 1 September 2026. Hans combines deep industry experience with a strong track record in stakeholder engagement, most recently serving as Global Head of External Engagement at Roche
Manufacturing
AlzeCure licenses Alzheimer’s candidate ACD680 to Lilly in deal worth up to $1bn
AlzeCure Pharma has entered a global licensing and collaboration agreement with Eli Lilly for its Alzheimer's disease candidate ACD680, securing a $10m upfront payment and potential milestone payments exceeding $1bn
Drug Delivery
Stevanato Group launches Deora pen injector platform targeting GLP-1 and incretin therapies
The fixed-dose, multi-use pull-push device accommodates volumes up to 0.75 mL, offering pharma partners a scalable, error-reducing delivery solution for diabetes and weight management programmes
Finance
GSK acquires Nuvalent for $10.6bn to accelerate NSCLC pipeline with FDA-reviewed ROS1 and ALK inhibitors
GSK has agreed to acquire clinical-stage oncology company Nuvalent for $10.6bn, securing two late-stage next-generation kinase inhibitors — zidesamtinib and neladalkib — currently under FDA review for potential 2026 approval in non-small cell lung cancer
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.